Cancel

Live Webinar: Diagnosis and Evidence-Based Management of T-Cell Lymphoma

Register today for this expert-led discussion presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health. This dynamic webinar will provide the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more! Don’t miss your chance to enhance y...
i3 Health

Infusing Renewed Hope into Cancer-related Anemia with Intravenous Iron: AN EXPERT-LED EXPLORATION OF RECENT AND EMERGING TRIAL DATA AND CURRENT GUIDELINE RECOMMENDATIONS

Designed and developed to maximize digital audience reach and engagement, this Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundat...
CE Concepts

Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape

Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now. STATEMENT OF NEED Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Rana...
i3 Health

Improving Outcomes in Hodgkin Lymphoma

This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now. STATEMENT OF NEED Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed ...
i3 Health

Updates in Myelodysplastic Syndromes: Improving Patient Outcomes

This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now. STATEMENT OF NEED Myelodysplastic syndromes (MDS) comprise a heterogeneous group ofmyeloid malignanciesthat derive from abnormal multipot...
i3 Health

New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia

Gain expert insight on new treatment approaches to improve outcomes for patients with immune thrombocytopenia, including individualized treatment for patients who relapse and strategies to alleviate and improve supportive care. This discussion is led by Howard Liebman, MD, Professor of Medicine and Pathology at the University of Southern California Keck School of Medicine, and Allison Miller lmahiyerobo, MSN, APN, Advanced Practice Nurse at Hematology and Oncology Physicians of Englewood. Star...
i3 Health

Research Highlights on Pyruvate Kinase (PK) Deficiency

This accredited CME activity provides a summary of the latest information about Pyruvate kinase (PK) deficiency that was presented at the 2021 American Society of Hematology Annual Meeting (ASH 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ASH 2021 and discuss this latest research, this program provides a review by Rachael Grace, MD, of the most clinically-relevant information on PK deficiency presented during the meeting. PK deficiency is a rare genetic b...
CheckRare

Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer

Join the discussion! We bring the expert to you. LIVE. VIRTUAL. FLEXIBLE. Interactive discussion on optimization of RET+ testing in NSCLC and thyroid cancer, and the pathways for enhancing collaboration between pathologists and oncologists to improve patient care. Choose a date that works best with your schedule! Your questions answered on precision medicine! - What are the roles of biomarkers? - When should biomarker testing occur? - What do the test results mean? - How does the muta...
ACHL

Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

Host a complimentary Virtual Visiting Professorship Program (VPP): Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2. Easy-to-administer one-hour complimentary virtual independent medical education is available to your institution. We will coordinate a day and time that works for your intuition and bring the expert to you. ✔️ No cost to your organization (supported by an educational grant) ✔️ Approved fo...
ACHL

Hot Topics in Oncology – Focus on the Immune Checkpoint Inhibitors (ICIs)

The immune checkpoint inhibitors (ICIs) continue to break ground in a multitude of cancer types. With ever-evolving data and recommendations, oncology clinicians must keep pace with the latest ICI updates. This recorded CME-certified session tackles questions surrounding topics related to immune checkpoint inhibitors with discussion on: • Role of biomarkers with ICI selection and monitoring • Latest expanded ICI indications • Immune-related adverse events This session also featu...
ACHL

Internal Medicine Comprehensive Review and Update 2022 - LIVE STREAMING

Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties This program, the 62nd Annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care. This program covers the breadth of Internal Medicine subspecialties, including: • Cardiovascular Medicine • Infectious...
Harvard Medical School

Safe and Effective Opioid Prescribing While Managing Acute and Chronic Pain

This course familiarizes physicians with current guidelines for opioid prescribing, including the management ofg acute and chronic back pain, how to assess the functional effects of pain in patients, and how to utilize a range of therapeutic options when managing patients with chronic pain. Outcome Objectives: As a result of completing this activity, the participant will be better able to: - Manage acute and chronic back pain. - Assess the functional effects of pain in patients. - A...
Virtual Lecture Hall (University of Arizona College of Medicine - Tucson)

Optimizing Outcomes in Cold Agglutinin Disease: Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic Agents

Target Audience This educational activity is directed toward hematologists and hematologist-oncologists who treat patients with cold agglutinin disease. Fellows, nurses, nurse practitioners, and other health care professionals interested in the management of patients with cold agglutinin disease are also invited to participate. Activity Overview Cold agglutinin disease (CAD) has a significant impact on patients’ quality of life. Historically, the limited availability of treatment op...
Physicians’ Education Resource®, LLC.

Addressing Barriers to Improved Outcomes in African American Patients With Multiple Myeloma

Target Audience This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses. Program Overview Multiple myeloma is the second most common blood cancer in the United States, and its incidence in the African American population is twice that of Whites. This activity offers learners the opportunity to engage in clinical scenarios of multiple myeloma in African American patients presented as 3 case vignettes, each featuring an expert-led video clip. Through the...
Practicing Clinicians Exchange.

Intensive Review of Internal Medicine - LIVE STREAMING

The Acclaimed Clinical Update and Board Review LIVE STREAMING and ON-DEMAND EDUCATION With more than 150 distance-learning lectures, case discussions, and board preparation sessions, this CME program is one of the most comprehensive reviews of internal medicine offered by the clinical faculty of Harvard Medical School. It offers accelerated learning: ► For clinicians seeking a practical and comprehensive review that ensures you are up to date across all major fields of internal med...
Harvard Medical School

Ocular Toxicities, Antibody-Drug Conjugates, and Multiple Myeloma: The Importance of Coordinating Ophthalmologic and Oncologic Care

The past two decades have seen the development of numerous new targeted therapies for multiple myeloma (MM). Included among these are antibody–drug conjugates (ADCs), which have shown significant promise in improving patient prognoses but are associated with unique adverse events (AEs). In particular, ADCs containing monomethyl auristatin F (MMAF) have been linked to increased incidence of corneal epithelial changes. With the FDA’s 2020 approval of belantamab mafodotin (the first ADC indic...
Postgraduate Institute for Medicine

RCC Treatment Strategies in a Poor-Risk Patient

Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and dis...
ACHL

Promoting Recognition, Diagnosis, and Treatment of Cold Agglutinin Disease

TARGET AUDIENCE: This activity was developed for adult hematologists, hematologist-oncologists, hematology-oncology nurse practitioners, emergency physicians, primary care physicians, and other clinicians involved in the management of patients with cold agglutinin disease. PROGRAM OVERVIEW: Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understandi...
Annenberg Center for Health Sciences at Eisenhower

RCC Treatment Strategies in a Favorable-Risk Patient

Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize o...
ACHL

Survival Skills for Today's Gynecologist

Survival Skills for Today’s Gynecologist is a three-day ACCME accredited conference in Washington, DC that focuses on enhancing your day-to-day office GYN practice. This course will teaching current, practical procedures and therapies that are easy to master, comfortable to incorporate and solidly reimbursable.
World Class CME

57th Annual Virtual Pediatric Post-Graduate Course

This course stems from Nicklaus Children's Health System’s tradition of quality and excellence in health care for children and is academically tailored to advance the clinical and research aspects of pediatrics and adolescent medicine. Renowned faculty from all over the United States and the world are invited to participate and present the most recent advances to the practicing pediatrician that directly impacts the practice. It is here that approximately 700 participants, including pediatri...
Nicklaus Children's Hospital

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Emerging Combinations for Newly Diagnosed CLL High-Risk Relapsed/Refractory (R/R) CLL

Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including BTK inhi...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC,

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Patient Selection

Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC,

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Aligning Patient and Provider Goals

Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the CLL Society (CLLS) and the Leukemia & Lymphoma Society (LLS).

Update in Hospital Medicine 2022 - LIVE STREAMING

Update in Hospital Medicine will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies. This 4-day intensive Harvard Medical School CME program updates busy practitioners on current, best practices in hospital medicine. Among the highest-rated HMS CME courses, it covers over 30 core topics, with an emphasis on practical management of common problems: • COVID-19 • Health equity/vulnerable populations • Heart failure • Atrial fibril...
Harvard Medical School

25th Annual General Pediatric Review and Self-Assessment

For 25 years now, Nicklaus Children’s Hospital Annual General Pediatric Review and Self-Assessment (Formerly known as the Pediatric Board Review Course) has led the way in educating healthcare professionals who are either taking the initial certifying examination or sitting for the re-certifying examination. In 2022, the 25th Annual General Pediatric Review and Self-Assessment will be held on May 12-15; 2022 at the W Hotel Fort Lauderdale; 401 N. Fort Lauderdale Beach Blvd; Fort Lauderdale, ...
Nicklaus Children's Hospital

Interprofessional Perspectives on Managing Immune-Related Adverse Events

The development of immunotherapies, including ICIs and CAR-T cell agents, is improving survival for some patients with cancer, even in advanced cases. These agents are associated with novel irAEs that are monitored and managed differently than the more familiar standard chemotherapy toxicities. Collaboration among members of the oncology care team is necessary to ensure that all healthcare providers, patients, and caregivers are educated about irAEs and their management. For all members of the...
American Academy of CME

The Role of the Oncology Nurse in the Diagnosis and Treatment of Castleman Disease

Target Audience This activity has been designed to address the educational needs of oncology nurses, including advanced practice nurses (APNs) and registered nurses (RNs). It will also benefit PAs and other clinicians who manage patients with Castleman disease. Program Overview Castleman disease (CD) is a rare group of heterogeneous lymphoproliferative disorders, many of which have an unknown underlying etiology. Owing to its rarity and unknown etiology, many oncology nurses are unaware o...
Global Education and Group Paradigm Medical Communications, LLC

DIAGNOSIS AND TREATMENT OF MF AND PV: Where Are We and Where Are We Going?

Target Audience This educational program is directed toward medical oncologists, hematologists, and other health care professionals who treat patients with MPNs. Fellows, researchers, nurse practitioners, nurses, physician assistants, and other allied professionals interested in hematologic malignancies are also invited to attend. Activity Overview Myeloproliferative neoplasms (MPNs) comprise a diverse range of hematologic cancers, with optimal management requiring careful risk stratifica...
Relias LLC

Rapid-Fire Roundtable on Melanoma: Focus on Advances in Adjuvant Treatment, Neoadjuvant Treatment, and Management of Metastatic Disease

Target Audience The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with advanced melanoma. Program Overview Treatment for patients with advanced melanoma has been revolutionized through the integration of immune checkpoint inhibitors (CPI) and targeted therapy into management algorithms. With these advances, new challenges have emerged, including identifying the patients who will benefit most from adjuvant and ...
Relias LLC

New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

Target Audience The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate. Activity Overview Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many var...
Physicians’ Education Resource®, LLC.

Real-World Experience in Diagnosing and Managing PNH in Special Patient Populations

In a “how I do it” clinical commentary, Dr. Jamile Shammo and Dr. Ilene Weitz share their real-world experience in the diagnosis and management of PNH in special patient populations. This case-based activity includes clinical scenarios and treatment strategies to improve patient outcomes.
ACHL

Answering the Call: Nurse-Led Strategies to Improve Compliance with Hemophilia Prophylaxis

Target Audience This educational activity is designed for advanced practice nurses (APRN) including nurses and nurse practitioners (NP), physicians, and other clinicians in a hematology setting treating patients with hemophilia A Program Overview Prophylactic management of hemophilia continues to be a challenge. The nurse-led activity discusses treatment strategies, safety and efficacy of current available products, and how to improve patient adherence. In this clinical commentary, expert...
Relias LLC

Medical Crossfire®: Personalized Regimens for Managing Hemophilia A: Selecting an Optimal Recombinant FVIII Agent

Target Audience This online educational activity is directed toward hematologists, primary care clinicians, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the management of hemophilia. Activity Overview Over the past 20 years, substantial advances in the treatment of hemophilia A have allowed patients to take greater control of their disease. The primary goals of hemophilia A treatment are to prevent bleeding episodes, reduce lon...
Relias LLC

A Glimpse Into Future of Myeloma Patient Management

ACTIVITY DESCRIPTION In the last 18 years, oncology clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. In this time, 16 new drugs have been approved by the US Food and Drug Administration (FDA) for use in MM—including 10 in the last 6 years alone. The rapidity with which clinical data ...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer

This recording from a series of expert-led small group meet-ups will increase your knowledge of RET inhibitors, help you gain confidence in utilizing biomarkers to inform treatment decisions, and improve collaboration between oncologists and pathologists to optimize precision medicine for RET-positive metastatic NSCLC and advanced thyroid cancer.
Penn State College of Medicine

Optimizing Management of Iron Overload: Strategies to Improve Identification and Treatment

Target Audience This educational program will be directed toward hematologists, pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with iron overload. Program Overview This online, on-demand virtual symposium brings together renowned experts in hematology and iron overload. In this educational program, these experts provide an overview of the pathophysiology and burden of iron overload as well as guideline-base...
Physicians’ Education Resource®, LLC.

Community Practice Connections™: Cold Agglutinin Disease: Shifting the Treatment Paradigm Through Improved Understanding of the Complement System

Target Audience The target audience for this activity is hematologists and hematologist-oncologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with CAD are also invited to attend.The target audience for this activity is hematologists and hematologist-oncologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with CAD are also inv...
Physicians’ Education Resource®, LLC.

Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management

B-cell non-Hodgkin lymphoma management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy—the majority of which do so because of adverse events (AEs)—and data suggest that the management of AEs is not consistent with recommendations. Moreover...
Lymphoma Research Foundation, RedMedEd, and Rutgers Biomedical and Health Sciences

Evaluating Emerging Gene Therapies to Further Treatment for Patients with Hemophilia A

Target Audience This initiative is intended for hemophilia specialists, hematologists, emergency department clinicians, nurses, medical geneticists, genetic counselors, and other healthcare providers who care for patients with hemophilia A. Program Overview Hemophilia A is an inherited bleeding disorders due to the partial or total deficiency of coagulation factor (F) VIII. Progress in hemophilia therapy has been remarkable over the last decades with the development of efficacious the...
AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Clinical Complications, Challenges, and Comorbidities Assoicated with Hemophilia A and its Treatment

Target Audience This initiative is intended for hemophilia specialists, hematologists, emergency department clinicians, nurses, medical geneticists, genetic counselors, and other healthcare providers who care for patients with hemophilia A. Program Overview Hemophilia A is an inherited bleeding disorders due to the partial or total deficiency of coagulation factor (F) VIII. Progress in hemophilia therapy has been remarkable over the last decades with the development of efficacious the...
Sanofi Genzyme and Takeda Pharmaceuticals U.S.A., Inc.

Selecting and Dosing Clotting Factors to Individualize Treatment for Patients with Hemophilia A

Target Audience This initiative is intended for hemophilia specialists, hematologists, emergency department clinicians, nurses, medical geneticists, genetic counselors, and other healthcare providers who care for patients with hemophilia A. Program Overview Hemophilia A is an inherited bleeding disorders due to the partial or total deficiency of coagulation factor (F) VIII. Progress in hemophilia therapy has been remarkable over the last decades with the development of efficacious the...
AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Expanding Patient Engagement to Advance Hemophilia A Treatment Adherence and Outcomes

Target Audience This initiative is intended for hemophilia specialists, hematologists, emergency department clinicians, nurses, medical geneticists, genetic counselors, and other healthcare providers who care for patients with hemophilia A. Program Overview Hemophilia A is an inherited bleeding disorders due to the partial or total deficiency of coagulation factor (F) VIII. Progress in hemophilia therapy has been remarkable over the last decades with the development of efficacious the...
AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Community Practice Connections™: Modifying the Course of Sickle Cell Disease With Modern Interventions

Target Audience The target audience for this activity is hematologists, specialty nurse practitioners, physician assistants, and registered nurses who treat patients with sickle cell disease. Other health care professionals interested in the treatment of sickle cell disease are also invited to participate. Program Overview Sickle cell disease consists of a group of rare genetic blood disorders which are responsible for serious life-threatening complications. In the past several years, a g...
Physicians’ Education Resource®, LLC

Community Practice Connections ®: New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

Target Audience The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate. Program Overview Nearly all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variable...
Physicians’ Education Resource®, LLC

Updates in Mantle Cell Lymphoma

Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now. STATEMENT OF NEED Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin ly...
i3 Health

Treatment Advances in Waldenstrom Macroglobulinemia

In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now. STATEMENT OF NEED Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphop...
i3 Health

Ace the Case: 79-Year-Old Man With Lower Back Pain, Increasing Fatigue, and Right Rib Pain

This activity utilizes a case study to discuss treatment options for transplant-ineligible multiple myeloma (MM) patients.
Penn State College of Medicine

A Comprehensive Review of Metastatic Colorectal Cancer (mCRC) Management: An Interprofessional Approach to Care

TARGET AUDIENCE: This activity is designed to meet the educational needs of oncologists, oncology nurses and pharmacists engaged in the care of patients with metastatic colorectal cancer. PROGRAM OVERVIEW: This interprofessional activity will cover: • Changes in treatment combinations and sequencing of regimens, as well as molecular markers that should be tested to guide therapy. • Supportive care measures and continual monitoring based on their therapy to ensure optimal outcomes an...
Relias LLC

AML 2021: Strategies for Attack Before Diagnosis and After Remission – Module 2

Target Audience This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers. Program Overview This activity provides an overview of important genetic mutations in acute myeloid leukemia and recent therapeutic advances. Learning Objective Upon completion of this activity, participants should be better able to: Identify the impact of minimal resid...
The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map